



(51) International Patent Classification:

C12N 9/22 (2006.01) C12N 15/87 (2006.01)
C12N 15/113 (2010.01) A61K 48/00 (2006.01)

(21) International Application Number:

PCT/US2022/024703

(22) International Filing Date:

13 April 2022 (13.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/174,468 13 April 2021 (13.04.2021) US

(71) Applicant: **ARSENAL BIOSCIENCES, INC.** [US/US];
2 Tower Place, Suite 700, South San Francisco, California
94080 (US).

(72) Inventors: **COOPER, Aaron**; c/o Arsenal Biosciences,
Inc., 2 Tower Place, Suite 700, South San Francisco, Cali-
fornia 94080 (US). **HSU, Pei-Ken**; c/o Arsenal Biosciences,
Inc., 2 Tower Place, Suite 700, South San Francisco, Cali-
fornia 94080 (US). **MOOT, Robert**; c/o Arsenal Bio-
sciences, Inc., 2 Tower Place, Suite 700, South San Fran-

cisco, California 94080 (US). **TRUONG, Annie**; c/o Arse-
nal Biosciences, Inc., 2 Tower Place, Suite 700, South San
Francisco, California 94080 (US). **GARDNER, Thomas**; c/
o Arsenal Biosciences, Inc., 2 Tower Place, Suite 700, South
San Francisco, California 94080 (US). **HSU, Brian**; c/o Ar-
senal Biosciences, Inc., 2 Tower Place, Suite 700, South San
Francisco, California 94080 (US).

(74) Agent: **RODRIGUEZ, Elena M.** et al.; Goodwin Procter
LLP, IP Docketing Dept./7TH FL, 100 Northern Avenue,
Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(54) Title: NON-VIRAL HOMOLOGY MEDIATED END JOINING




FIG. 1

(57) Abstract: Provided herein are compositions and methods for producing genetically engineered cells, such as T cells, with an insertion of a cassette at a designated genomic locus using non-viral gene editing techniques. Methods of using the genetically engineered cells for treating or preventing a disease in a subject are also provided.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*